The real-time PCR is a powerful tool for the detection and quantification of viral nucleic acids. This method has a number of advantages for routine diagnostics, including multiplex capability, a wide dynamic range, and reduced risks of contamination (1 ) . At present, real-time detection and quantification of target sequences can be achieved with several technologies, such as those incorporating intercalating dyes, probe-based chemistries (such as TaqMan assays), and primer-based chemistries (such as Scorpion probes) (2, 3 ) . For clinical applications, the presence of an internal control sequence that is amplified simultaneously with the target sequence is required to validate negative results (4) (5) (6) (7) (8) ; hence, the use of real-time multiplex assays is highly recommended.
Measurement of viral load is important for detecting infections caused by herpesviruses, such as human cytomegalovirus (HCMV), 4 Epstein-Barr virus (EBV), and varicella-zoster virus (VZV) (9 ) . Infections caused by HCMV, EBV, and VZV have different clinical consequences; however, all can cause critical outcomes in immunocompromised patients (10, 11 ) . Accordingly, highly reliable real-time PCR assays must be used to correctly identify samples that are positive and negative for these viruses (8, 9 ) . Fluorescent amplicon generation (FLAG) was recently described as a primer-based signal-generation technology for detecting mutations (12 ) and DNA hypermethylation (13 ) . In the present study, we have included an accessory oligonucleotide (an "anchor") in the FLAG assay (a-FLAG). This anchor assists in the binding of the fluorogenic primer by promoting the formation of a highly specific ternary structure, the 3-way junction (14, 15 ) . The formation of the 3-way junction is the initiation event that triggers the amplification reaction. We have adapted a-FLAG for the detection of nucleic acids from 3 viruses (HCMV, EBV, and VZV) in the presence of an internal amplification-control reaction. We compared the performance of the HCMV a-FLAG assay with a commercially available product currently used for detecting and quantifying HCMV in clinical samples.
Materials and Methods

SOURCE AND EXTRACTION OF HCMV DNA
Purified and quantified HCMV, EBV, and VZV genomic DNA was obtained from Advanced Biotechnologies. HCMV DNA concentrations were checked with the artus CMV RG PCR Kit (Qiagen) and with the Q-CMV Real Time Complete Kit (Nanogen Advanced Diagnostics). 
GENERATION OF pCMV STANDARD PLASMID
The exon 4 sequence of HCMV gene UL122 was amplified from purified HCMV DNA with primers AD99 (5Ј-TTTAAGCTTGGGGCCGGTGCTACTGGAAT-3Ј) and AD100 (5Ј-TTTCTCGAGATGTGAGCGGGGC ATCGAG A-3Ј). We then digested the 1 512-bp amplicon with HindIII and XhoI (New England Biolabs) and subcloned into pCR2.1 vector (Invitrogen). Plasmid DNA was then purified with the Qiagen QIAfilter Plasmid Midi Kit and quantified by spectrophotometry. Dilutions were prepared in 1ϫ Tris-EDTA buffer (described above) containing 20 ng/L yeast total RNA. Concentrations were checked with the artus CMV RG PCR Kit and the Q-CMV Real Time Complete Kit according to the manufacturers' protocols.
GENERATION OF INTERNAL-CONTROL PLASMID
We amplified the human ␤-globin gene (HBB, 5 hemoglobin, beta) with primers ES102 (5Ј-CCCTCTAAG ATATATCTCTTGGCC-3Ј) and ES103 (5Ј-AGAAA AACAACAACAAATGAATGCA-3Ј) and blunt-cloned the 415-bp amplicon into pCR-Blunt vector (Invitrogen). Plasmid DNA was purified with the QIAfilter Plasmid Midi Kit and quantified by spectrophotometry. Dilutions were prepared in 1ϫ Tris-EDTA buffer containing 20 ng/L yeast total RNA.
TARGET SELECTION AND OLIGONUCLEOTIDE DESIGN
We designed oligonucleotides to amplify DNA regions that do not contain PspGI restriction sites. These regions were within the exon 4 sequence of the UL122 gene of the HCMV AD169 strain (GenBank accession number, NC_001347.3), the BNRF-1 gene of EBV strain B95-8 (accession number, V01555.2), and the UL29 gene of VZV strain Dumas (accession number, X04370). We used Visual OMP software (DNA Software) to check each oligonucleotide for cross-hybridization with any of the other oligonucleotides. Fluorogenic primers were labeled with Iowa Black FQ (IBFQ) and either internal fluorescein (iFluorT) or internal MAX NHS ester (iMAXn). All oligonucleotides were synthesized by Integrated DNA Technologies. 
, 75 nmol/L AD70 (internal control reverse primer: 5Ј-TTTCCAGGTTCACAG CTTGGTAAGCATATTGAAGATCG-3Ј), 25 fg/L internal control plasmid, and 20 L of sample. After a first decontamination step at 50°C for 2 min and denaturation at 95°C for 2 min, reactions were performed for 45 cycles of 95°C for 10 s, 60°C for 30 s, and 68°C for 32 s. Reactions were performed in a 7500 Real-Time PCR System (Applied Biosystems). Fluorescence was monitored during the 68°C step in the FAM and VIC channels; thresholds were set at relative units of 0.05 and 0.02, respectively, with ROX normalization. The baseline was calculated between cycles 6 and 12. All reactions were performed in triplicate except where otherwise indicated. At least 4 calibrators (pCMV) and 1 no-target control were included in each run. Results were considered valid when HCMV amplification occurred before the 45th cycle or when amplification of the internal control occurred between cycles 23-27. Each run was considered valid for quantification if the regression coefficient for the threshold cycles of calibrators was at least 0.990.
EBV a-FLAG ASSAY
EBV a-FLAG reactions were carried out in the Applied Biosystems 7500 Real-Time PCR System as described for the HCMV a-FLAG assay except that the following EBV-specific oligonucleotides were used: 125 nmol/L EG61QF [EBV fluorogenic primer: 
Results a-FLAG REACTION
The FLAG system uses the thermostable restriction enzyme PspGI to cleave a fluorophore-quencher pair that is present at the end of double-stranded amplification products (12, 13 ) . In this work, we introduced an accessory oligonucleotide ("anchor") to facilitate the annealing of the forward primer (see Supplemental Figure 1 and Supplemental Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol54/issue11), which carries at the 5Ј end an 11-base sequence tag containing a fluorophore-quencher pair separated by a restricted site for PspGI. After an initial denaturation step, the anchor and the fluorogenic primer hybridize to the target DNA to form a 3-way DNA junction (Fig.  1A) . The 3Ј end of the anchor oligonucleotide is modified with a terminal dideoxycytidine and therefore cannot be extended by the polymerase; the fluorogenic primer, on the other hand, is extended at its 3Ј end. The opposite strand of the target DNA is bound by an unlabeled reverse primer. To equilibrate the thermodynamic contribution of the accessory sequences in the fluorogenic primer, we added an unlabeled 11-base sequence tag at the 5Ј end of the reverse primer. In the next cycle of the reaction, the sequence-tag region becomes double-stranded (Fig. 1B) , allowing recognition and cleavage by PspGI and the generation of a fluorescence signal (Fig. 1C) . The a-FLAG reaction is summarized in 3 steps. The anchor and the fluorogenic primer hybridize to one strand of the target DNA to form a 3-way DNA junction (step A); the fluorogenic primer carries a sequence tag that contains a fluorophore-quencher pair (F-Q) separated by a restriction site. In the following cycles, the extension of the reverse primer on the first amplification product completes the double-stranded recognition site for PspGI (step B), allowing cleavage and fluorescence generation (step C). Arrows indicate the 3Ј end of each DNA sequence; the solid dot indicates the terminal dideoxycytidine (ddC).
a-FLAG ASSAYS FOR HCMV, EBV, AND VZV
a-FLAG assays for HCMV, EBV, and VZV were designed as duplex reactions for the selected viral genomic DNA and for the human HBB gene, which was used as an internal amplification control. We tested serial dilutions of quantified viral DNA with the a-FLAG assay and monitored fluorescence profiles for viral DNA and internal amplification controls in real time (Fig. 2, A, D, G , B, E, and H). A linear relationship was observed between the measured threshold cycle and the input concentration of viral DNA (Fig. 2, C, F , and I). The efficiency of viral DNA amplification was calculated from the slope of the regression line, and the 3 assays had similar efficiencies (HCMV, 0.79; EBV, 0.84; VZV, 0.83). As expected, the amplification of the internal control was inversely affected by the target-DNA concentration because of competition for common reagents (Fig. 2, B , E, and H).
LINEAR RANGE
To standardize the target DNA used in different experiments, we subcloned the exon 4 sequence of the UL122 gene of HCMV into pCR2.1 vector and used the resulting plasmid (pCMV) for the calibration curves. We quantified pCMV serial dilutions either by spectrophotometry or with 2 reference kits (artus CMV RG PCR Kit, Q-CMV Real Time Complete Kit). To analyze the extent of the linear relationship between the measured signal (threshold cycle) and the initial concentration of target DNA, we tested previously quantified serial dilutions of pCMV standard plasmid (from 5 ϫ 10 10 copies/L to 0.5 copies/L) in triplicate. We ob- (Fig. 3A) . Because the efficiency calculated for the amplification of pCMV DNA (0.82) was similar to that previously observed for HCMV genomic DNA (0.79), we assumed that pCMV DNA and HCMV DNA were substantially equivalent. We subsequently evaluated the linear range of the assay by quantifying serial dilutions of HCMV DNA from nominal concentrations of 10 7 copies/L to 1 copy/L and observed a linear relationship between expected and calculated concentrations throughout the considered range (slope, 1.02; r ϭ 0.9980; Fig. 3B ). We did not observe significant differences when human genomic DNA solutions (up to 25 ng/L) were used as the matrix for diluting HCMV DNA (data not shown).
LIMIT OF DETECTION
The limit of detection of the assay was defined as the lowest concentration of HCMV DNA at which the assay could distinguish a positive sample from negative samples 95% of the time. We diluted HCMV DNA extracted from a high-titer clinical sample to nominal concentrations of 1-0.001 copies/L and tested 8 replicates of the dilutions in 3 independent runs. We then plotted the percentage of positive results for each sample against the logarithm of the input concentration and used the best-fitting cumulative standard distribution equation to calculate the concentration corresponding to 95% of the positive results. The calculated concentration was 0.420 copies/L; that is, the assay was able to detect as few as 8.40 copies of HCMV DNA per reaction 95% of the time (Fig. 4) . Given the extraction procedure used (QIAamp MinElute Virus Spin Kit; input volume, 200 L; output volume, 100 L), this value corresponds to a concentration in a clinical sample of 210 copies/mL, assuming a 100% extraction efficiency.
REPRODUCIBILITY
Interassay imprecision was analyzed in 20 runs, with a single replicate per run, on 5 samples of HCMV DNA. Intraassay imprecision was analyzed for the same samples in a single run, with 10 replicates (a confirmation experiment was performed). Calculated minimum, maximum, and mean values, the SD, and the CV are presented in Table 1 . As expected, interassay CV values were higher than intraassay CV values. Sample A, which had the lowest concentration of all the analyzed samples (1.5 copies/L), had the highest observed interassay and intraassay CVs (46.97% and 32.72%, respectively).
COMPARISON OF THE a-FLAG HCMV ASSAY WITH THE artus CMV RG PCR KIT
We compared the a-FLAG HCMV assay performance and the results for the artus CMV RG PCR Kit by using Fig. 5 ), resulting in a diagnostic sensitivity of 99%. Similarly, we found 54 of 57 artus-negative samples also to be negative in the a-FLAG assay, resulting in a diagnostic specificity of 95%. Four samples produced discordant results: 1 sample was negative in the a-FLAG assay and positive in the artus method, and 3 samples were positive by the a-FLAG assay and negative in the artus assay. Threshold cycle values for these 4 samples indicated that their concentrations were below the limit of detection of both methods. We excluded the possibility of the presence of inhibitors in the reaction, because all of the discordant samples were validated with the internal amplification control. We also assessed the cross-reactivity of the a-FLAG HCMV assay with a panel of different herpesviruses (EBV; VZV; human herpesviruses 6a, 6b, and 8; herpes simplex viruses types 1 and 2); no cross-reactivity was observed (data not shown). 
Discussion
The usefulness of the diagnostic real-time PCR in virology is well established, because the rate of disease progression has been shown in many viral diseases to be directly related to the amount of viral nucleic acid that can be detected in plasma, serum, or peripheral blood lymphocytes. In immunosuppressed patients, such as recipients of solid-organ or bone marrow transplants, the clinical need to monitor HCMV, EBV, and VZV infections by quantifying the viral DNA in the blood has been well documented (8) (9) (10) (16) (17) (18) . The anchor-based FLAG assay presented in this work provides an alternative method for detecting these 3 viruses. This assay combines diagnostic sensitivity with the diagnostic specificity required for clinical applications. We modified the originally described FLAG assay by introducing a third oligonucleotide (the anchor) to ensure a highly specific initiation event for the amplification reaction. This additional oligonucleotide forms a stable heteroduplex with the target DNA (16 ), enabling the formation of a specific ternary structure with the fluorogenic primer. The resulting 3-way junction (target-anchor-fluorogenic primer, Fig. 1A ) has a calculated ⌬G°2 times higher than a regular PCR primer or the fluorogenic primer alone (HCMV 3-way junction, Ϫ23.42 kcal/mol; HCMV fluorogenic primer alone, Ϫ10.13 kcal/mol; HCMV reverse primer, Ϫ12.31 kcal/mol) (see Fig. 1 and Table 1 in the online Data Supplement). The thermodynamic contribution of the anchor allows one to use the primers at lower concentrations, thus reducing the risk of forming primer dimers in samples with negligible or no target DNA (2 ) . Moreover, the cost of the labeled oligonucleotides required for each reaction is reduced. We developed 3 different assays (for HCMV, EBV, and VZV DNA) that share the same internal amplification-control system and display very similar performances in terms of the efficiency of the reaction. We further evaluated the HCMV a-FLAG assay by calculating the limit of detection, evaluating interassay and intraassay imprecision, and comparing the results with those obtained with the commercially available artus CMV RG PCR Kit. In the absence of an international standard for HCMV DNA quantification (only proficiency panels are available), we decided to assign the titer of our calibrators with the artus CMV RG PCR Kit. The 2 assays showed comparable values with respect to the linear range, the limit of detection, and interassay and intraassay imprecision. The results of our quantification of DNA in the 128 plasma samples obtained with the 2 methods showed a good correlation. We observed discordant results for only 4 samples that had concentrations below the limit of detection of both assays. The internal amplification control allowed us to exclude the presence of PCR inhibitors, because none of the discordant samples had atypical threshold cycle values for the internal control.
These results demonstrate that the a-FLAG technique could be applied to the detection and quantification of HCMV, EBV, and VZV DNA in the presence of an internal amplification control. This and previous work (12, 13 ) indicate that the FLAG principle could be adapted to develop real-time assays for a wide range of clinical applications.
